Overview

Capecitabine Plus Toripalimab Maintenance Therapy in Metastatic Nasopharyngeal Carcinoma After First-line Treatment

Status:
Not yet recruiting

Trial end date:
2029-09-01

Target enrollment:

Participant gender:

Summary

to evaluate the efficacy and safety of toripalimab and capecitabine maintenance therapy in patients with metastatic nasopharyngeal carcinoma (NPC) after first-line gemcitabine/cisplatin combined with toripalimab.

Phase:

Phase 2

Details

Lead Sponsor:

Affiliated Cancer Hospital & Institute of Guangzhou Medical University

Collaborators:

Hunan Cancer Hospital
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Treatments:

Capecitabine